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Abstract
Background: Hepatitis C virus (HCV) infection causes a large number of deaths annually worldwide. Policies play an
important role in regulating healthcare agendas and prioritising of health-related issues. Understanding these priorities
is very important in health. The objective of this study was to investigate HCV-related issues and their influence on
agenda-setting in Iran.
Methods: A qualitative design was used. Data were collected by carrying out a review of documents and interviews.
A comprehensive search was conducted to identify documents related to HCV-related policies in Iran. Semi-structured
interviews were conducted with both purposive and snowball sampling of 14 interviewees related to the HCV
programme in Iran, including government officials, civil society, development partnership members and academicians.
Documents and interview data were analysed manually and using MAXQDA Version 10 software. Kingdon’s multiple
streams framework was used to guide data analysis.
Results: The factors which influenced HCV-related agenda-setting were lack of proper information of the HCV
epidemiology before the 1990s, lack of diagnostic facilities, neighbouring countries with high HCV prevalence,
the stigma of HCV, high prevalence in prisoners, international evidence and high costs generated by HCV. The
factors related to policy were effective treatment methods, drug production inside Iran, Iran Hepatitis Network,
support outside government group elites and academicians. The factors related to political will were international
influence, changes in the government and parliament support.
Conclusion: The findings of this study showed that there are various national and international factors that play
a role in shaping HCV-related policies. It seems that, if HCV is put into the agenda, it can be eliminated in Iran by
2030 by supporting and implementing appropriate programmes from decision- and policy-makers.
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Background
Hepatitis C virus (HCV) infection causes a large number
of deaths annually worldwide [1] and has become one of
the key healthcare challenges [2]. It is estimated that 1% of
the world’s population (approximately 71 million people)
is infected with HCV [3]. Despite the introduction of
direct-acting antiviral drugs in different countries, with
preliminary promising results, the number of deaths due
to this infection continues to increase [4]. The high cost
of the drugs used, the limited capacity of laboratories and
other facilities, the lack of financial resources in the health
sector and the lack of support for many policy- and
decision-makers in low- and middle-income countries
represent some major barriers to the proper access to
treatment of patients with HCV [5].
Various countries worldwide have implemented appro-
priate policies to reduce the incidence and mortality of
HCV, whilst designing and developing plans to control
this public health problem in the years to come [6–8].
To control HCV, effective policies are needed that re-
quire the efforts of international, regional and national
stakeholders. Participation of these stakeholders creates
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a high political commitment and mobilises all resources
to implement these policies [9, 10].
Advocacy in HCV control programmes has led to
achievement of effective patient treatment and manage-
ment goals as well as a reduction in the costs of medicines
through the establishment of pharmaceutical companies to
produce medicines locally overcoming the need to buy
them from third countries [2]. Additionally, advocacy of
the country’s stakeholders is an important and vital element
integral to healthcare policy [11]. To prevent, control and
cure a disease, new policies need to be implemented or
existing policies must be changed [12], both of which are
very complex policy processes [13]. Policy- and decision-
makers decide on the various issues affecting the health
sector, including the amount of personal interest, the mag-
nitude of the topic, the available scientific evidence, political
and social considerations, the efforts of interest groups and
their impact on the topic. All these issues can influence the
decision of health policy- and decision-makers of whether
to place a topic on their agenda [14]. Thus, various factors
can impact on the process of agenda-setting and should be
taken into consideration [15].
Existing policies to control HCV can accelerate the
process of reducing, and even eliminating, its burden if
they are taken seriously by policy- and decision-makers
and put on their agenda [16]. When a major issue, such
as HCV, is put into action, comprehensive support for
the issue will make policies work properly; thus, the role
of policy- and decision-makers in the success or failure
of an important policy is of crucial importance [17]. For
an issue like HCV to become a priority, complex pro-
cesses are undertaken; the priority of a policy or
programme is defined by the degree of policy- and
decision-makers’ attention to financial, human, and tech-
nical issues and resources that can be used or mobilised
to implement that policy [18].
HCV in Iran is an important public health challenge
and should be addressed by health policy- and
decision-makers. Despite the low prevalence of HCV in
the general Iranian population, the infection is on the rise
[19]. It is expected that, in the near future, this infection
will be the most important cause of deaths related to
hepatitis in Iran [20]. Its high prevalence is particularly
alarming in high-risk groups such as injecting drug users
(IDUs) and prisoners [21, 22]. Undoubtedly, HCV should
be placed on policy- and decision-makers’ agenda. Policies
play a vital role in health issues related to community
health, and therefore understanding the relevant fac-
tors that can impact on the process of agenda-setting
is very important.
The present investigation aimed to better understand
HCV-related issues and their impact on policies in Iran.
To achieve this, Kingdon’s multiple streams framework
was deemed suitable for the purpose and, as such, was
selected for this study. This framework is an appropriate
technique for the planned analysis in that it enables the
exploration of HCV-related issues and the effects they
have on the process of agenda-setting. Being this the
first analysis on HCV-related issues and their impact on
policies in Iran, the investigation was conducted at a
macro-level (national level), rather than focusing on a
single region or province.
The theoretical framework
Kingdon’s multiple streams framework is one of the
most used conceptual tools for understanding the
process of policy-making, including policies in the field
of healthcare. This instrument enables scholars to cap-
ture the different steps of the policy-making process,
including how policies are developed and implemented
and which are the obstacles (lack of interest, lack of
clarity and ambiguity, among others) that hinder the
full implementation of a given policy. In detail, King-
don’s framework includes three elements or independ-
ent streams. Providing appropriate conditions for an
interaction among these three issues will cause oppor-
tunities to be created and will facilitate the process of
agenda-setting by policy- and decision-makers [23]. As
previously mentioned, this framework can be used to
explain how different policies have addressed various
topics in the health sector [24–32].
One of these streams is the ‘problem’ stream. This
stream includes indicators, focusing events or feedback
mechanisms. Indicators include issues that health policy-
and decision-makers, researchers, doctors, and other
stakeholders can achieve in their daily routine monitoring
activity or scientific research. Policy- and decision-makers
can use these indicators to determine the impact of a topic
and evaluate different scenarios about them. Some exam-
ples of these indicators include the outbreak of a disease,
the rate of death from road accidents, the shortage of
manpower and increased healthcare costs. Focusing
events such as a tragedy, a crisis or a disaster can trigger
policy- and decision-makers’ feedback on a given issue.
Many indicators alone cannot determine the importance
of an issue, which is rather given by the complex interac-
tions among indicators. Within Kingdon’s framework, sev-
eral actors, such as government officials, the media,
interest groups, industries, legislators and constituents, as
well as other stakeholders, play a major role.
The second of Kingdon’s streams is the ‘policy’ stream.
This stream involves potential solutions to the problem
and allows individuals and groups to work on a solution
to further develop it. Actors involved in this process can
include lawmakers, special interest groups, policy entre-
preneurs, professionals, academicians and industry re-
searchers. These people can provide different alternatives
or problems, issues and situations in order to influence
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the process of agenda-setting. Factors such as the level
of support for individuals and groups, costs, industries
and past experiences can also influence the choice of
alternatives.
The final stream in Kingdon’s model is the ‘political’
stream. National mood, shifts in administration, media
influence, interest group advocacy campaigns, elections
and ministerial changes can have an impact on the process
of policy- and decision-making. In addition, legislators
and administrators also have an influence on political
processes.
Based on Kingdon’s model, the interaction of these three
streams determines the process of agenda-setting. Policies
are implemented effectively when all of these streams con-
verge, resulting in a policy window. Policy entrepreneurs
can facilitate this process and create opportunities for pol-
icy progress. As previously stated, the aim of this study
was to investigate the determinants of the process of
agenda-setting of HCV-related issues in Iran.
Methods
Data collection
Data were collected by carrying out a comprehensive re-
view of relevant HCV-related documents and interviews.
Document analysis
A comprehensive search was conducted to identify doc-
uments related to HCV issues and policies, contained in
scholarly publications as well as in the grey literature in
Iran. The websites of the different pertinent ministries
and related organisations, such as the Ministry of Health
and Medical Education (MoHME), the Parliament (Maj-
lis), the Iranian Judicial system, the Ministry of Coopera-
tives, Labour and Social Welfare, the State Prisons and
Security and Corrective Measures Organisation, the Red
Crescent, the Imam Khomeini Relief Foundation, and
the Ministry of Sport and Youth, were consulted.
Additionally, scholarly databases, including PubMed/
MEDLINE, ISI/Web of Science, EMBASE and Scopus,
were searched from January 1990 up to July 2018, using
a string of keywords related to the topic under study.
Google Scholar was used to retrieve the grey literature.
Concerning the search strategy, the following keywords
were selected: (policy OR policies OR plans OR pro-
grams OR strategies OR solutions) AND (‘hepatitis C
virus’ OR ‘viral hepatitis’ OR HCV) AND Iran.
National guidelines, training manuals and handbooks,
health reports, national health plans, international, national
and regional policies, health protocols, non-governmental
organisation (NGO) reports, and HCV-related laws were
also searched; this search was done independently by two
authors in order to identify all documents.
Semi-structured interviews
Semi-structured interviews were conducted with both
purposive and snowball sampling of 14 interviewees re-
lated to the HCV programme in Iran, including govern-
ment officials, civil society, development partnership
members and academicians. These people were in-
volved in the planning, decision-making, policy-making
and support of HCV programmes.
Interviews were digitally recorded and saved using a
tape recorder. During the interview, a handwritten
note was also prepared. The interview time was be-
tween 45 and 70 min. Interview data accuracy was
achieved by reviewing the handwritten texts by inter-
viewees and using their complementary comments as
well as involving well-trained researchers in the
process. In addition, two experts in the field of quali-
tative studies monitored the whole interview process.
The use of an integrative method, including note-tak-
ing during interviews and a sampling method ensuring
maximum diversity, provided data reliability and
transferability [33].
With regards to policies concerning HCV, the follow-
ing questions were asked:
1. Problem stream: What challenges still unresolved
and unaddressed make HCV a problem in Iran?
2. Policy stream: What solutions have been found and
adopted by individuals or groups to address
HCV-related issues in Iran?
3. Political stream: What are the political factors that
can influence the effective adoption of HCV-related
policies in Iran?
Analytical approach
Data extracted from documents and interviews were
analysed both manually and using MAXQDA Version 10
software for content analysis. Following familiarisation
with the data and a preliminary analysis of the inter-
views, initial codes were prepared and, after removing
the same duplicate codes, they were interpreted and fi-
nally assigned under the themes of Kingdon’s multiple
streams framework (problem, policy and political
streams). The principles of content analysis were applied
to guide and inform the data analysis.
Ethics
Written, informed consent was obtained from each par-
ticipant after a clear and thorough explanation of the
study objectives and assurance of the confidentiality of
one’s own identity. Ethical approval for this study was
obtained from the authors’ institute prior the com-
mencement of the investigation.
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Results
According to Kingdon’s framework, the effective factors
associated with HCV-related issues and policies, which
can be described as a priority in Iran, can be analysed and
subdivided into the problem, policy and political streams.
Problem stream
Lack of proper information on HCV before the 1990s
The participants stressed that, until the 1990s, there was
not enough information on HCV in Iran concerning the
number of patients with HCV and the epidemiological
and clinical burden of the disease. Indeed, no attention
was paid to this disease, and remained inadequately ad-
dressed by the healthcare departments and institutions.
Only after the advent of contaminated blood, HCV
began to be considered as an issue by policy- and
decision-makers.
Diagnostic facilities
The respondents stated that, in the same years, labora-
tory facilities were limited in their ability to diagnose
the disease due to the costs, and therefore many people
were not able to identify their illness due to lack of
diagnostic facilities.
Neighbouring countries with high prevalence of HCV
The participants stated that the prevalence of HCV in
Iran is lower than in its neighbouring countries, such as
Iraq, Afghanistan, Pakistan, Turkey, Azerbaijan and
Tajikistan, which have a high HCV prevalence rate. The
movement of people from these countries to Iran, espe-
cially those at a higher risk, could cause the transmission
of new cases.
Transit from Afghanistan and increased number of addicts
The respondents declared that Afghanistan, the largest
producer of narcotics in the world and one of Iran’s
neighbouring countries, is one of the main trafficking
routes. Hence, the number of IDUs in Iran has increased
and, according to the available scientific evidence, the
prevalence of HCV among these individuals is high and
has raised serious concerns.
HCV and stigma
The respondents stressed that, for cultural and religious
issues, the stigma of HCV is high in Iran. Due to low
awareness among people about HCV, many of them
consider HCV-infected individuals as HIV-positive,
which has isolated patients and made them refrain from
pursuing their diagnosis and treatment. People with
HCV have fear and anxiety, and are not willing to col-
laborate with physicians and be treated because they feel
blamed for their condition.
High HCV prevalence in prisoners
The respondents stressed that the various studies have
shown that HCV levels in prisoners are higher than in
other populations in the community. The high-risk be-
haviours that exist in prisons can provide the basis for
the high prevalence of this disease. On the other hand,
prison officials, for various reasons, are not willing to
cooperate fully with diagnostic and therapeutic proce-
dures, and they have problems with providing prisoners
with syringes.
International evidence
The participants stated that, in its 2017 report on hepa-
titis, WHO announced that the Middle Eastern region,
including Iran, has a low-moderate HCV prevalence, ex-
cept for some areas with high levels of HCV infection.
However, according to this report, the death rate from
hepatitis has increased between 2005 and 2015, and is
alarmingly high for Iran.
High costs of HCV
The respondents stressed that the costs generated by
HCV treatment and management are high and many pa-
tients are not able to pay for them. The MoHME’s fund-
ing for this disease is limited and therefore the lack of
attention to these patients causes serious problems for
them and other people in the community. The MoHME
alone cannot afford all HCV-related costs. If patients are
not supported, they will avoid treatment, causing many
people at risk of contracting HCV to actually contract it.
Increased HCV in IDUs
IDUs are considered worldwide as one of the most im-
portant high-risk groups for HCV infection. They repre-
sent an alarming issue for all countries, including the
health sector in Iran.
Policy stream
To combat HCV, various alternatives can be used in the
areas of prevention, screening and treatment. Hence,
these alternatives can help policy- and decision-makers
to find ways to eradicate HCV in their country.
Effective treatment methods
The participants stressed that, in recent years, drug
treatments for HCV have led to an effective option
for managing this disease, with many countries having
used available therapeutic solutions for eradicating
this disease. Support from the MoHME in Iran pro-
vided the basis for the treatment of these patients.
Establishing a diagnostic network in governmental la-
boratories and delivering patient medications would
provide a way for better interventions to improve the
status of HCV patients.
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Drug production inside Iran
The interviewees declared that the support of pharmaceut-
ical companies plays an important role in the process of
treating and managing HCV patients. Expensive drugs ne-
cessary for curing this disease can be a barrier to the treat-
ment of patients. Therefore, pharmaceutical companies in
Iran, with private and government sector investments,
have started producing HCV drugs and significantly curb-
ing their prices.
Iran Hepatitis Network (IHN)
The respondents stressed that individuals and groups at
home and abroad supported HCV control programmes.
The IHN, a government-affiliated entity, consists of spe-
cialised physicians, laboratory staff and experts in the
field of HCV providing annual training, identification
and treatment of HCV patients, and screening of people
at a higher risk with high levels of protection. The IHN’s
activities are unique – the IHN has been able to offer
prevention and disseminate high-quality information. It
has also been able to convince many political groups in
the community that HCV should be given more atten-
tion. People in this network all have a high level of ex-
pertise in HCV-related areas.
Support outside government groups
The interviewees stated that the NGOs and community-
based organisations play an important role in preventing
crime and social exclusion. NGOs represent a social cap-
ital for governments. These NGOs have advocated HCV
prevention policies in recent years. Various campaigns
that have led to increased awareness among the general
population have, to some extent, contributed to the im-
provement of information on the disease. Campaigns in
schools, universities, drug addiction centres and parks
organised by these NGOs have raised awareness of
HCV. Moreover, with the participation of the people,
stigma towards HCV patients has decreased.
Elites and academicians
The respondents stressed that elites and academicians
doing research in the field of HCV can be very effective
in prioritising the disease. Professor Reza Malekzadeh is
Deputy of Research and Technology of the MoHME in
Iran; he has been the minister of health in previous years
and is one of the most renowned academic figures in
Iran and the world. His views on specialised committees
such as the Hepatitis Committee and meetings with
other organisations for HCV are important and can
therefore influence their decisions. He has been able to
encourage pharmaceutical companies to produce HCV
drugs and he also plays a valuable role in providing sci-
entific evidence and research studies.
The judicial system supports harm reduction programmes
in prisons
The Iranian judicial system has effectively supported
harm reduction programmes among prisoners and has




The respondents stressed that the 2015 Sustainable
Development Goals (SDGs) played an important role in
emphasising the fight against HCV, and one of the goals
to eliminate HCV has been identified by the year 2030.
The SDGs have made Iran’s policy- and decision-makers
to be willing to commit to achieving the goal of elimin-
ating HCV by 2030.
Changes in the government
The respondents stressed that, with the start of the
government of President Rouhani, health promotion
was introduced as one of his most important campaign
slogans. In 2014, the Health Transformation Plan
started with a variety of goals. Over time, different goals
have been considered, introduced and gradually
achieved. Additionally, the control of infectious dis-
eases such as HCV was a serious target. With the
launch of this plan, health was seen as a serious priority
among Parliament and decision- and policy-makers in
Iran. Appropriate funding was allocated to the plan,
leading to the development of less advanced areas that
did not have a good health status.
Parliament support
The participants stated that, when matters are consid-
ered by the Parliament, the required rules are passed fas-
ter and more accurately. Certified people at the
Parliament’s Health Commission try to find new sources
of funding for health-related issues, including HCV, in
order to achieve better health and reduce mortality
among members of the community. Individuals in Par-
liament in many cases can help to improve the health
status of the community and can change the cultural
perspective of society with new and appropriate laws.
Discussion
Policies play an important role in regulating the process
of agenda-setting and prioritising of health-related is-
sues. Understanding these priorities is very important in
the field of healthcare. The use of Kingdon’s multiple
streams framework in this study helped us to examine
the different dimensions and factors of HCV-related is-
sues based on three streams (namely, problem, policy
and political will) in Iran.
Behzadifar et al. Health Research Policy and Systems           (2019) 17:30 Page 5 of 10
The results showed that, if properly understood and
effectively utilised, the use of conceptual frameworks,
such as Kingdon’s theoretical tool, can provide an appro-
priate and deep understanding of the impact of several
health-related issues on policy- and decision-makers.
HCV epidemiology in Iran
Indicators in the public and private sectors can be uti-
lised as warnings for policy- and decision-makers. Exist-
ing evidence and scholarly studies on the epidemiology
of HCV in Iran indicate that the incidence/prevalence
rate of this disease is not high yet many people with this
condition are not aware of their infection state [34, 35].
Furthermore, due to the easy transfer within neighbour-
ing countries, the transmission of various diseases has
made health policy- and decision-makers more aware of
the disease with regards to the specific regional situation
[36]. People from various neighbouring countries to Iran
undergo numerous trips to some of Iran’s religious cities.
Many Afghans entered the Sistan and Baluchestan prov-
ince via the Eastern border of Iran, and given the higher
prevalence of HCV in Afghanistan, there is a risk of
transmission and contagion from these travellers. In the
past, there have also been some similar experiences with
viral hepatitis [37].
HCV drugs and related costs
Health policy- and decision-makers look for cost-effect-
ive alternatives since HCV treatment, prevention and
management can be costly for the country’s health sys-
tem [38]. The existence of effective HCV therapeutics
able to eradicate the virus should stimulate policy- and
decision-makers to find solutions in order address this
disease in a sustainable way [39]. The cost of HCV
treatment is indeed high and, according to the global
guidelines and suggestions from health institutional
bodies, the HCV drugs should be included in the list of
essential therapeutics [40]. Many patients are not able
to start or complete their treatment due to a lack of fi-
nancial support from the health departments and lack
of insurance coverage [41]. Policy- and decision-makers
in Iran stated insufficient funding for the provision of
drugs and medicines to treat HCV patients. Further-
more, medications were limited and the Ministry of
Health was confronted with important limitations re-
garding the availability of drugs. Drug production inside
a given country can reduce local drug prices. Indeed,
Egypt’s experiences in drug production and the subse-
quent reduction of drug prices are a good example to
follow [42]. Further, encouragement and support from
the Iranian Ministry of Health has raised interest from
pharmaceutical companies to produce drugs within
Iran, with a subsequent reduction in the cost of these
medications. Additionally, insurance companies are also
keen to cover the cost of drugs and treatment for pa-
tients since this is significantly lower than before.
Involvement of stakeholders in the process of decision-
and policy-making
The role of policy communities as groups that involve in-
dividuals with expertise in a field is important in providing
ideas and innovations in the field of healthcare policies
[43]. IHN consists of specialised network of people who
play a very important role with regards to HCV-related is-
sues. The presence of people who, in the past, have served
as important managers in the MoHME’s network can pro-
vide good ideas for enriching, developing and effectively
implementing HCV-related programmes.
Disagreements between associations and groups often
occur when discussing various issues; however, in Iran,
given the importance of controlling this disease, good
convergence has been established between many groups,
NGOs and the IHN. Indeed, various groups and NGOs
in Iran are trying to focus on HCV issues regardless of
their own interests, with integrity and team work to
achieve the elimination of HCV. According to Kingdon’s
model, one of the destructive effects of fragmentation
between groups is insecurity and instability [23], and
lack of consensus due to different orientations [44].
However, despite the diversity of groups involved in the
treatment or management of various diseases, including
HCV, their activities are being carried out in pursuit of
the same goal – the fight against HCV. Further, there
can be many actors in relation to a policy [45]; these ac-
tors can be either inside or outside government. Within
the government, employees of the Ministry of Health,
government groups and organisations give their support
for the elimination of HCV, and outside the government
body, private groups and companies have agreed to im-
plement HCV control programmes [46].
The convergence of different stakeholders leads to
more attention from policy- and decision-makers [47].
Although people in the various groups have different
goals, if an important issue such as HCV, the elimination
of which is critical for the overall community health, is
on the agenda, this convergence can be valuable [48].
Global actors and their influence on HCV-related policies
in Iran
The findings of this study presented some of the influen-
tial factors in the political stream impacting on HCV
elimination policy in Iran; globalisation is one of these
factors [49]. The Millennium Development Goals experi-
ence and commitment by countries to achieve them in
2015 showed that policy- and decision-makers from
various countries are keen to increase the quality of life
for people in terms of health indicators [50]. Unfortu-
nately, the Millennium Development Goals did not focus
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much on HCV, likely leading to the increasing epidemio-
logical burden (prevalence/incidence rate) of the disease
in the past years. Conversely, all countries within the
SDGs have pledged to eliminate HCV by 2030 [51].
Local political events and their influence on agenda-setting
Elections and changes in government are among the most
important political events that can have meaningful effects
in prioritising a given policy [52, 53]. The new Iranian
government, which was settled in 2013, announced
healthcare as one of its slogans. After winning the elec-
tion, health policy- and decision-makers enforced a
healthcare reform. In the first step, the goal was to reduce
people’s out-of-pocket expenses and to spread health
equity [54]. Over time, various programmes have been im-
plemented in this reform, and the increase of access to
health services in less developed regions and high-risk in-
dividuals has also been of interest to policy- and
decision-makers; programmes to control various infec-
tious diseases were also included in this package. The
most important part of this reform was the allocation of
new financial resources for health. Therefore, policy- and
decision-makers, with more financial resources, tried to
expand their financial support for different patient groups,
with HCV seemingly receiving more attention in light of
the new conditions [37]. As individuals are involved in the
decision- and policy-making process, they usually support
certain policies, creating coalitions and striving to priori-
tise given policies [23]. The existence of influential people
can facilitate the process of agenda-setting since their pos-
ition allows them to convince policy- and decision-makers
to focus on a given policy [55]. In the Iranian Parliament,
certain individuals can convince other decision- and
policy-makers to focus on issues such as HCV. In recent
years, the Iranian parliament has supported health sector
programmes and has adopted good laws.
Window of opportunity and policy entrepreneurs
According to Kingdon’s model, if all the three issues of
problem, policy and political will are linked, the likelihood
of an issue being on the agenda is very high [23]. Thus,
the ‘window of opportunity’ for HCV appears to be open
in Iran. Policy-makers have different and appropriate evi-
dence to take advantage of this opportunity window.
When the goal of HCV elimination by 2030 was set as
a target by WHO in the SDGs, a new opportunity win-
dow was created. WHO, with the cooperation and com-
mitment made by all countries and through the
cooperation of all stakeholders, has made many efforts
towards the achievement of this goal. With the imple-
mentation of the Health Transformation Plan, the
Iranian government has begun to prioritise
health-related issues and HCV has also been of interest
both to decision- and policy-makers.
The documentation on infectious diseases has indi-
cated that Iranian decision- and policy-makers are, in-
deed, interested in controlling HCV. On the other hand,
not all stakeholders have shown the same level of inter-
est and commitment towards the development and im-
plementation of some HCV-related policies.
The interviewees stated that the most important
HCV-related actor, the MoHME, is acting as a policy entre-
preneur, but needs the support of all the other stakeholders.
Comparison with other studies
The existing scholarly literature focusing on policy pro-
cesses in low- and middle-income countries analysed by
means of Kingdon’s multiple streams framework is ra-
ther limited. Few studies have explored such topics. A
recently published investigation, conducted in Kenya
[56], addressed some of the major health challenges this
country is experiencing and the obstacles hindering the
full implementation of intersectoral collaborations and
actions focusing on health promotion. In Iran [57], a
qualitative case study approach was employed to address
the ‘Health in All Policies’ programme; Kingdon’s model
was utilised at the micro-level (province level) and polit-
ical commitment and policy entrepreneurs were found
to be the two most relevant leverages in the political
process. In Cameroon [58], the policy analysis of
performance-based financing in the healthcare sector
showed the importance of setting a dedicated team in
order to implement and pursue the policy. The process
of decision- and policy-making was also influenced by
other factors, including available media information, sci-
entific evidence, and previous policies and experiences.
Other studies are from developed countries, such as
Ireland [59], Canada [60] and United Kingdom [61]. In
Ireland [59], Kingdon’s multiple streams theory has been
used to analyse and provide recommendations regarding
diabetes care. Authors were able to describe the non-con-
vergence of the politics stream due to the lack of support
from health service management, changes at the level of
the organisational structure and lack of adequate funding.
In Canada [60], the theoretical framework was used to in-
vestigate HPV vaccination-related issues, underlining how
the existence of cost-effectiveness models and advocacy of
stakeholders, including citizens and HPV-affected politi-
cians, influenced the government in deciding to fund the
immunisation campaign also for male subjects. In the
United Kingdom [61], using this model, the author was
able to uncover continuities and discontinuities in the
problem, politics and policy streams over the past 70 years
of the British National Health Service.
All these studies have found Kingdon’s multiple
streams tool to be informative and useful in providing
an accurate analysis reflecting the different stages and
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steps of decision- and policy-making, in terms of oppor-
tunities, obstacles and challenges.
Strengths and limitations
This study has some strengths and limitations that
should be properly acknowledged. The strengths include
the use of a well-known conceptual framework
(Kingdon’s multiple streams model), which enables
scholars to collect relevant data and to perform an ac-
curate analysis of HCV-related issues and their impact
on policies in Iran. Kingdon’s model is, indeed, a valu-
able structured tool, which focuses on the different as-
pects of the processes of policy- and decision-making.
Besides methodological rigor and transparency, another
strength of the present investigation is given by its nov-
elty, in that it explores a topic usually overlooked in the
existing scholarly literature. There is, indeed, a dearth of
data and information about healthcare-related decision-
and policy-making in low- and middle-income countries.
On the other hand, this study suffers from some limi-
tations. For instance, the sample of participants was not
completely representative of the entire civil society.
Moreover, the study design was cross-sectional and not
longitudinal. Finally, the focus of this article was national
and not regional, and it failed to address the cultural
and social differences that may exist in different prov-
inces of Iran.
Future prospects
Based on the above-mentioned shortcomings, further
research is urgently needed in the field. Future studies
should employ a larger sample size, perhaps utilising a
randomised sampling technique, and a longitudinal
study design in order to capture time trends and tem-
poral patterns. Additionally, a regional focus should be
adopted in order to collect relevant actionable data
useful for policy- and decision-makers at the meso-
and micro-levels.
Conclusion
The present study examined HCV-related issues as a
priority for Iran’s healthcare system using Kingdon’s
multiple streams framework. The findings of this inves-
tigation showed that there are various national and
international factors that may play a role and influence
the process of agenda-setting. The epidemiology of this
disease as a global challenge, the support of various
groups and the existence of political changes in Iran
are among the factors that have led HCV to be consid-
ered a priority. It can be anticipated that, if HCV is put
on policy- and decision-makers’ agenda, HCV can be
eliminated in Iran by 2030 by supporting and imple-
menting appropriate policy programmes.
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